FDA-approved1,2Evidence: Large human trialsGut and digestion

Linaclotide1

Also called Linzess1

Key takeaway

Linaclotide is a lab-made peptide related to guanylin and uroguanylin, natural gut hormones, and is the active ingredient in AbbVie’s Linzess.1,2 It is FDA-approved for irritable bowel syndrome with constipation in adults and children aged 7 and older, chronic idiopathic constipation in adults, and functional constipation in children aged 2 and older.1 Its adult approvals rest on large randomized, placebo-controlled trials of about 600 to 800 adults each described in the label.1 The label carries a boxed warning: it is contraindicated in children younger than 2 because it caused deaths from dehydration in young mice.1

Linaclotide at a glance

What it isA guanylate cyclase-C agonist that the label says acts locally on the lining of the intestine.1
FDA statusFDA-approved. Drugs@FDA lists Linzess with an original approval date of August 30, 2012. The label carries a boxed warning about serious dehydration in children younger than 2.1,2
Human evidenceLarge randomized, placebo-controlled trials in adults and randomized trials in children, described in the label.1
Evidence strengthLarge randomized human trials. The cited sources include at least one fully reported randomized, controlled human trial with 300 or more participants, or a trial that a regulator cites as a basis for approval. How this label is assigned

What is linaclotide?

Linaclotide is a lab-made peptide that the label describes as structurally related to guanylin and uroguanylin, hormones made in the gut.1

Drugs@FDA lists it as the active ingredient of Linzess, from AbbVie, and of generic linaclotide applications approved in 2021 and 2023.2,3,4

How does linaclotide work?

The label states that linaclotide and its active breakdown product activate guanylate cyclase-C on the surface of the intestinal lining. This increases a signalling molecule, cGMP, which draws chloride, bicarbonate and fluid into the intestine and speeds transit.1

The label also states that in animal models linaclotide reduced intestinal pain and the activity of pain-sensing nerves.1

What do human studies show?

The label describes two randomized, double-blind, placebo-controlled trials in adults with irritable bowel syndrome with constipation, with 800 and 804 participants. In both, a statistically significantly higher proportion of people responded to linaclotide than to placebo, based on combined pain and bowel-movement measures.1

Two further trials in adults with chronic idiopathic constipation, with 642 and 630 participants, and randomized trials in children are also described in the label.1

Diarrhea was the most common adverse reaction: in the adult irritable bowel syndrome trials it affected 20% of people taking linaclotide and 3% on placebo, and was severe in 2%, according to the label.1

What the evidence base contains

  • Large randomized human trial Two randomized, double-blind, placebo-controlled trials in irritable bowel syndrome with constipation (NCT00948818 and NCT00938717), with 800 and 804 adults evaluated for efficacy.1
  • Large randomized human trial Two randomized, double-blind, placebo-controlled trials in chronic idiopathic constipation, with 642 and 630 adults evaluated for efficacy.1
  • Controlled human trial A 12-week randomized, double-blind, placebo-controlled trial in 328 children aged 6 to 17 with functional constipation.1

Evidence-strength label: Large randomized human trials. How this label is assigned

Is linaclotide FDA-approved?

Yes. Drugs@FDA lists Linzess, application NDA202811, with an original approval date of August 30, 2012, and generic linaclotide applications approved on February 9, 2021 and February 7, 2023.2,3,4

The Linzess label cited here (DailyMed SPL version 39, published June 1, 2026) states that it is indicated for irritable bowel syndrome with constipation in adults and children aged 7 and older, chronic idiopathic constipation in adults, and functional constipation in children aged 2 and older.1

The label carries a boxed warning: linaclotide is contraindicated in children younger than 2, because in studies in newborn mice it caused deaths due to dehydration.1

The label also states that it is contraindicated in people with known or suspected mechanical blockage of the gut, and warns about diarrhea, which can be severe.1

Timeline

  1. FDA approves Linzess, according to Drugs@FDA.2
  2. FDA approves a generic linaclotide application, according to Drugs@FDA.3
  3. DailyMed publishes the Linzess label version cited on this page.1

What is still unknown?

Its safety in children younger than 2, for whom the label says it is contraindicated.1

Its long-term effects: the main adult trials lasted 12 to 26 weeks.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Linaclotide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Linaclotide are the records PeptideScanner has selected and published, not every registration or paper about Linaclotide. A daily check adds newly updated registrations and newly indexed papers that pass the publication checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Linzess. Large randomized, placebo-controlled trials described in the label support its adult uses. The label carries a boxed warning: it is contraindicated in children younger than 2 because of a risk of serious dehydration.↗↗

Status sources checked through July 22, 2026. See status sources and coverage →

What do the reviewed human studies say?

Human evidence reviewed September 20, 2026 · Review version 2.

Review source snapshots checked September 20, 2026 · Integrity checked September 20, 2026.

Two publications report adult chronic-constipation trials and a pediatric functional-constipation trial. They do not cover the full irritable-bowel-syndrome program or every currently labeled age group.↗↗

What the reviewed sources report

Randomized trials reported improved bowel-movement measures over 12 weeks. Diarrhea is an important adverse effect; the pediatric trial included a serious dehydration event related to severe diarrhea.↗↗

What remains unresolved?

  • What additional trials address irritable bowel syndrome and other age groups?↗↗
  • How do current regulatory labels and longer follow-up refine the safety assessment?↗↗

Read study designs, results, limitations, and sources →

What does the U.S. product label say?

Linzess · Read September 15, 2026 · Preserved label summary 1

Which population and use does the label cover?

The June 2026 label distinguishes IBS with constipation in adults and children aged seven years and older, chronic idiopathic constipation in adults, and functional constipation in children aged two years and older. Label: 1 ↗

Which safety limits matter?

The boxed warning concerns serious dehydration in children younger than two, for whom the product is contraindicated. The label also lists known or suspected mechanical gastrointestinal obstruction as a contraindication and describes potentially severe diarrhea. Label: 1, 4, 5, boxed warning ↗

Label edition and source pins

U.S. product labeling hosted by the National Library of Medicine. This account concerns this product and label edition; other formulations and jurisdictions require their own records.

LINZESS (linaclotide) capsule · SPL version 39 · published 2026-06-01

Label ZIP SHA-256: 77c54fc2bf053002e1fd77970d745d4088919827b5a4a74d5d139cf8df320a54. Extracted XML SHA-256: 0e36407b126e3d4b3c616c030ed28362be4484ad305e337e12c319145523082a.

Open versioned label context data →

Reviews summarize selected studies; their scope and limitations are shown above.

Read the full Human Evidence Review

Supervised synthesis

What do selected human studies report about Linaclotide?

Manually reviewed September 20, 2026 · version 2

Browse all Human Evidence Reviews · Open preserved synthesis version 2 →

Two publications report adult chronic-constipation trials and a pediatric functional-constipation trial. They do not cover the full irritable-bowel-syndrome program or every currently labeled age group.12

Bottom line from this bounded source set

Randomized trials reported improved bowel-movement measures over 12 weeks. Diarrhea is an important adverse effect; the pediatric trial included a serious dehydration event related to severe diarrhea.12

Reviewed study record

Adult chronic constipation: Trial 303

Design

A randomized, double-blind, placebo-controlled 12-week trial tested two active groups.1

Population

Adults with chronic constipation participated; the abstract reports 1,276 participants across Trials 303 and 01 together, without a separate Trial 303 count.1

Outcomes reported

The primary bowel-response endpoint was reached by 21.2% and 19.4% in the two active groups, compared with 3.3% with placebo.1

Limitations

These are the Trial 303 efficacy results. The abstract’s 4.2% diarrhea-related discontinuation figure is reported across active groups in the two-trial publication and is not a separately appraised Trial 303 safety estimate. Follow-up was 12 weeks.1

Reviewed study record

Adult chronic constipation: Trial 01

Design

A randomized, double-blind, placebo-controlled 12-week trial tested two active groups.1

Population

Adults with chronic constipation participated; the abstract reports 1,276 participants across Trials 303 and 01 together, without a separate Trial 01 count.1

Outcomes reported

The primary bowel-response endpoint was reached by 16.0% and 21.3% in the two active groups, compared with 6.0% with placebo.1

Limitations

These are the Trial 01 efficacy results. The abstract’s combined participant count and diarrhea-related discontinuation figure should not be assigned to Trial 01 alone. Follow-up was 12 weeks.1

Reviewed study record

Pediatric functional constipation

Design

Randomized, double-blind, placebo-controlled phase 3 trial lasting 12 weeks.2

Population

330 children aged 6–17 years were randomized; 328 received treatment and 293 completed.2

Outcomes reported

The adjusted between-group difference was 1.17 additional spontaneous bowel movements per week. Diarrhea occurred in seven of 164 active-group and three of 164 placebo participants; one active-group participant required hospitalization for dehydration.2

Limitations

The trial addresses functional constipation in the enrolled age range. Its findings cannot establish safety in younger children or replace age-specific label warnings.2

Reviewed source set

  1. PubMed · 21830967Two randomized trials of linaclotide for chronic constipation. ↗PubMed PMID 21830967 · EFetch XML reviewed 2026-09-20 · payload SHA-256 24d773849646882ab3031eef6fc3481ce604a26f409a13a58e22a2004aca0a3b
    No registered Crossref update in the reviewed snapshotChecked September 20, 2026 for DOI 10.1056/nejmoa1010863. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
  2. PubMed · 38211604Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. ↗PubMed PMID 38211604 · EFetch XML reviewed 2026-09-15 · payload SHA-256 58b2d55045c664eb19aec9f97374ea3268f561017615f37584eb189d4c41c982
    No registered Crossref update in the reviewed snapshotChecked September 15, 2026 for DOI 10.1016/s2468-1253(23)00398-9. This bounded result is not proof that the publication has never been corrected or retracted. Open the pinned Crossref work endpoint ↗
Official-source readings

Inside the official reviews

Reviewed 2026-09-19 · Preserved version 1

What a constipation responder meant

In the original FDA chronic idiopathic constipation review, response required at least three complete spontaneous bowel movements per week and at least one more than baseline, during at least nine of twelve weeks. This is a defined trial threshold, not a claim that every symptom resolved. FDA PDF pp. 30 ↗

More findings, study links and document coverage

Benefit was demonstrated over a limited interval

Two placebo-controlled phase 3 trials, LIN-MD-01 and MCP-103-303, supported the constipation finding. FDA noted low absolute responder proportions despite statistically significant differences, and no efficacy-durability data beyond sixteen weeks in that submission. FDA PDF pp. 30 ↗

Diarrhea mattered to tolerability

Diarrhea was the most common adverse event and reason for discontinuation in the reviewed clinical program. Most cases were mild or moderate; this does not mean treatment was well tolerated by every participant. FDA PDF pp. 30 ↗

Separate the clinical programs

The combined file also contains a separate adult irritable bowel syndrome with constipation review. These selected pages appraise the original chronic idiopathic constipation account, not the IBS-C evidence or later pediatric extensions. FDA PDF pp. 17, 267, 30 ↗

Read the separate U.S. label account → Label version and indication scope are preserved there; these agency reviews describe their own dated evidence.

Document coverage

Selected sections read in 1 of 23 inventoried documents; 22 not yet reviewed. Reading selected sections does not establish complete appraisal of a document.

Selected English EMA PDFs from the retained September 15, 2026 title-matched document feed, plus independently retrieved FDA approval-package documents where listed. Candidate entries are not verified product/application matches. This is a bounded inventory, not a complete FDA, national or worldwide source search. EMA inventory source ↗

Inspect documents, application identities and source pins

Page references use one-based PDF file pages, which can differ from printed page numbers. Candidate feed associations are not verified application identities.

Remaining work

  • Read the separate IBS-C clinical review and later pediatric approval documents.
  • Reconcile longer-term efficacy and safety reports with the original short-term trials.

Open versioned document coverage and study pins →

European medicine records · 1 products or applications

EMA medicine metadata checked 2026-09-15. These are product-specific centralized records; national European authorizations and full product-information assessments require separate coverage.

Application withdrawal and refusal are distinct from marketing authorization. A withdrawal status alone does not establish why it occurred. These metadata entries do not substitute for indication, population or safety details in the relevant product information.

Open versioned records and source-feed pins →

Research coverage and study families

Search and screening record checked 2026-09-15. Counts describe records, not independent trials. Full-text appraisal is separate from an abstract review.

Open machine-readable coverage and record decisions →

PubMed search

Identity/name search without publication-type filtering; primary human reports, extensions, combinations and other reports require separate eligibility decisions. Known selected reports were recovered.

477 retrieved · 2 included · 0 excluded · 475 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

"linaclotide"[Title/Abstract] OR "Linzess"[Title/Abstract] OR "Constella"[Title/Abstract]

  • Full-text appraisal and screening of unassessed records remain open.
  • Registry comparison, additional aliases and references, and regulator reconciliation require separate checks.

Showing 25 of 477 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. PubMed 38211604 — include: Selected human report; abstract and record metadata reviewed. Study families: NCT04026113.
  2. PubMed 21830967 — include: Selected human report; abstract and record metadata reviewed. Study families: NCT00730015; NCT00765882.
  3. PubMed 42319080 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  4. PubMed 42695347 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  5. PubMed 42702764 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  6. PubMed 42694017 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  7. PubMed 42283961 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  8. PubMed 42242129 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  9. PubMed 42681900 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  10. PubMed 42676398 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  11. PubMed 42569232 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  12. PubMed 42425925 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  13. PubMed 42612545 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  14. PubMed 42523615 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  15. PubMed 42482900 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  16. PubMed 42465095 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  17. PubMed 41913506 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  18. PubMed 39950440 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  19. PubMed 42278633 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  20. PubMed 41692643 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  21. PubMed 41987372 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  22. PubMed 42083746 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  23. PubMed 42066057 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  24. PubMed 41413756 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.
  25. PubMed 41123247 — not screened: Retrieved identity/name match; clinical eligibility has not yet been adjudicated.

FDA search

Active-ingredient name query in openFDA Drugs@FDA. Returned application identities include salt forms and combination products; exact indications, approval conditions, supplements and marketing status require document-level review.

4 retrieved · 4 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

products.active_ingredients.name:"LINACLOTIDE"

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T11:10:19.050259+00:00 · HTTP 200 · SHA-256 4ca45091d9b10f758b1c006b68001601f064b335e2dcdf2b90a511e46a7eb8a7.

  • Zero results describe this query response only, not absence of FDA approval or worldwide nonapproval.
  • This endpoint does not inventory every label, advisory proceeding, safety communication or regulatory document. Application inclusion does not establish current marketing or approval of every use.

Showing 4 of 4 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. FDA NDA202811 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LINACLOTIDE.
  2. FDA ANDA209564 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LINACLOTIDE.
  3. FDA ANDA211255 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LINACLOTIDE.
  4. FDA ANDA209611 — include: Retrieved application lists a matching ingredient or its salt; document and product review remain separate. Listed ingredients: LINACLOTIDE.

EMA search

Local matching in the pinned EMA medicines feed; document matches also use identified EMA product numbers. This is not every national European record.

1 retrieved · 1 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Linaclotide", "Linzess"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:22.905972+00:00 · HTTP 200 · SHA-256 a947c2b8a56ac2b92ec96156843f262f5e516f83b375d6791d67a8f6dc695729.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 1 of 1 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. EMA EMEA/H/C/002490 — include: EMA feed product Constella; reported status: Authorised. Exact indication and decision documents remain unappraised.

EMA search

Local matching in the pinned EMA documents feed; document matches also use identified EMA product numbers. This is not every national European record.

22 retrieved · 16 included · 0 excluded · 6 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Linaclotide", "Linzess"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:29.167460+00:00 · HTTP 200 · SHA-256 c0c68d7d77783e0355cbc75bdd04772e9acc163236fc68abcd794477c4c3d439.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 22 of 22 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

  1. EMA 9966 — include: Document linked by EMA product number; content unappraised. Constella-H-C-2490-PSUV-09 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation
  2. EMA 28212 — include: Document linked by EMA product number; content unappraised. Constella-H-C-PSUSA-00010025-201508 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
  3. EMA 30350 — include: Document linked by EMA product number; content unappraised. Constella : EPAR - All Authorised presentations
  4. EMA 35371 — include: Document linked by EMA product number; content unappraised. Constella : EPAR - Summary for the public
  5. EMA 40909 — include: Document linked by EMA product number; content unappraised. Constella : EPAR - Public assessment report
  6. EMA 45239 — include: Document linked by EMA product number; content unappraised. Constella-H-C-2490-P46-013 : EPAR - Assessment report
  7. EMA 47891 — include: Document linked by EMA product number; content unappraised. Constella-H-C-PSUSA-00010025-201908 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
  8. EMA 55862 — include: Document linked by EMA product number; content unappraised. Constella-H-C-2490-P46-017 : EPAR - Assessment report
  9. EMA 58685 — include: Document linked by EMA product number; content unappraised. Constella-H-C-2490-P46-019 : EPAR - Assessment report
  10. EMA 58766 — include: Document linked by EMA product number; content unappraised. Constella-H-C-2490-P46-018 : EPAR - Assessment report
  11. EMA 63724 — include: Document linked by EMA product number; content unappraised. Constella : EPAR - Risk management plan
  12. EMA 69064 — include: Document linked by EMA product number; content unappraised. Constella-H-C-002490-P46-020 : EPAR - Assessment report
  13. EMA 33744 — include: Document linked by EMA product number; content unappraised. Constella : EPAR - Procedural steps taken and scientific information after authorisation (archive)
  14. EMA 72289 — include: Document linked by EMA product number; content unappraised. Constella : EPAR - Procedural steps taken and scientific information after authorisation
  15. EMA 74280 — include: Document linked by EMA product number; content unappraised. Constella-PSUSA-00010025-202508 : EPAR - Scientific conclusions and grounds for the variation to the terms of the marketing authorisation
  16. EMA 13191 — include: Document linked by EMA product number; content unappraised. Constella : EPAR - Product Information
  17. EMA 60891 — not screened: Title-name match awaiting identity and document review. P/0529/2022: EMA decision of 30 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for linaclotide (Constella), (EMEA-000927-PIP01-10-M07)
  18. EMA 50429 — not screened: Title-name match awaiting identity and document review. P/0216/2021 : EMA decision of 8 June 2021 on the acceptance of a modification of an agreed paediatric investigation plan for linaclotide (Constella) (EMEA-000927-PIP01-10-M06)
  19. EMA 5926 — not screened: Title-name match awaiting identity and document review. P/0252/2016: EMA decision of 26 September 2016 on the acceptance of a modification of an agreed paediatric investigation plan for linaclotide (Constella), (EMEA-000927-PIP01-10-M03)
  20. EMA 32832 — not screened: Title-name match awaiting identity and document review. P/110/2011: EMA decision of 6 May 2011 on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver for linaclotide (EMEA-000927-PIP01-10)
  21. EMA 37470 — not screened: Title-name match awaiting identity and document review. P/0106/2013: EMA decision of 30 April 2013 on the acceptance of a modification of an agreed paediatric investigation plan for linaclotide (Constella), (EMEA-000927-PIP01-10-M01)
  22. EMA 68951 — not screened: Title-name match awaiting identity and document review. P/0207/2024: EMA decision of 14 June 2024 on the acceptance of a modification of an agreed paediatric investigation plan for linaclotide (Constella) (EMEA-000927-PIP01-10-M08)

EMA search

Local matching in the pinned EMA orphans feed; document matches also use identified EMA product numbers. This is not every national European record.

0 retrieved · 0 included · 0 excluded · 0 awaiting a decision · 0 full-text appraisals

Search terms, record decisions and remaining work

Case-insensitive word-boundary identity terms: ["Linaclotide", "Linzess"]

Source retrievals and payload pins
  • Open the source endpoint ↗

    Retrieved 2026-09-15T08:34:31.262344+00:00 · HTTP 200 · SHA-256 7448bf4e77e3345b3f3fbb7062c335d2302d8ea458a246bbe8256ce48aad2806.

  • Document appraisal and national European sources remain open.
  • Zero matches apply only to these feed fields and terms; orphan designation is not approval.

Showing 0 of 0 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    ClinicalTrials.gov search

    ClinicalTrials.gov name/alias discovery, including cited product names. Matches may concern combinations, background references or different formulations; identity and outcomes need screening.

    63 retrieved · 0 included · 0 excluded · 63 awaiting a decision · 0 full-text appraisals

    Search terms, record decisions and remaining work

    "Linaclotide" OR "Linzess" OR "Constella"

    Source retrievals and payload pins
    • Open the source endpoint ↗

      Retrieved 2026-09-15T11:26:27.505907+00:00 · HTTP 200 · SHA-256 23b2996ef03aae49ccc09c32aa0fc9fc4520332ae325d405cce0544e739d2fce.

    • Registration is not evidence that a study succeeded, that results were published, or that a use is approved.
    • Other registries, unregistered studies and additional aliases remain outside this query.

    Showing 25 of 63 record decisions, with included studies and unresolved records first. The versioned data inventory retains every record and study-family link.

    1. ClinicalTrials.gov NCT01427387 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    2. ClinicalTrials.gov NCT03336034 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    3. ClinicalTrials.gov NCT00306748 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    4. ClinicalTrials.gov NCT02270983 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    5. ClinicalTrials.gov NCT00460811 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    6. ClinicalTrials.gov NCT00948818 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    7. ClinicalTrials.gov NCT03224494 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    8. ClinicalTrials.gov NCT00765882 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    9. ClinicalTrials.gov NCT07569419 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    10. ClinicalTrials.gov NCT00339690 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    11. ClinicalTrials.gov NCT02465385 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    12. ClinicalTrials.gov NCT00730171 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    13. ClinicalTrials.gov NCT06692673 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    14. ClinicalTrials.gov NCT00402337 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    15. ClinicalTrials.gov NCT05796388 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    16. ClinicalTrials.gov NCT02837783 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    17. ClinicalTrials.gov NCT01880424 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    18. ClinicalTrials.gov NCT02590432 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    19. ClinicalTrials.gov NCT02291679 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    20. ClinicalTrials.gov NCT06989268 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    21. ClinicalTrials.gov NCT04532879 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    22. ClinicalTrials.gov NCT04110145 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    23. ClinicalTrials.gov NCT02809105 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    24. ClinicalTrials.gov NCT02316899 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    25. ClinicalTrials.gov NCT03796884 — not screened: Registry name-query match awaiting intervention identity, study-family linkage and results appraisal.
    Explore status sources, recent additions, and coverage gaps

    Living status brief

    What is the current status of Linaclotide?

    FDA-approved as Linzess. Large randomized, placebo-controlled trials described in the label support its adult uses. The label carries a boxed warning: it is contraindicated in children younger than 2 because of a risk of serious dehydration.↗↗

    The cited status sources were checked through July 22, 2026. This answer changes only through the profile’s visible version and correction history.

    Evidence present

    What records are connected here?

    Evidence lanes
    4
    Source years
    15
    Drugs@FDA applications
    4

    These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

    Latest source-dated record

    What changed most recently at a cited source?

    Regulatory · source date October 19, 2026

    Linaclotide DailyMed SPL version 40↗Added to PeptideScanner November 15, 2026

    Coverage gaps

    What remains unknown or unsupported?

    All four evidence lanes appear in this selected collection, but their presence does not establish completeness, agreement, research quality, safety, effectiveness, approval, availability, or suitability.

    PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

    Explore the Evidence Map and record counts

    Evidence Map v1

    What kinds of records connect to Linaclotide?

    Compare collection coverage →

    This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

    102Selected dated records
    103Connected citations
    15Populated source years2012–2026
    4/4Record lanes present

    Registered human studies

    Trial composition

    5 of 15 selected trial records include at least one phase value; 5 of 15 include a status value in the retained structured contract.

    218 public history versions connect to 13 of these trial records across 19 submitted years. Open the record-history collection →

    PhasesPhase 2 2Phase 3 2Not applicable 1
    Status at observationCompleted 3Active, not recruiting 1Recruiting 1

    A phase value is unavailable here for 10 selected records; this is not counted as “no phase.”

    A status value is unavailable here for 10 selected records; this is not counted as a trial status.

    PubMed bibliography

    Publication composition

    25 of 49 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

    Publication typesJournal Article 21Comment 5Research Support, Non-U.S. Gov't 4Letter 3Review 3Randomized Controlled Trial 2Clinical Trial 1Clinical Trial, Phase II 1Clinical Trial, Phase III 1Editorial 1

    Bibliography fields unavailable here for 24 selected records; the records remain visible as metadata observations.

    Regulatory and publication surfaces

    What is structurally connected?

    Drugs@FDA applications
    4
    FDA Federal Register documents
    4
    DailyMed SPL versions
    29
    Canonical profile
    Published
    Profile structured data
    Published
    Linked dated records
    102

    Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

    Profile publication history and record counts
    Source records by collection · 102 dated records

    Research hub

    Explore the Linaclotide evidence record

    Open all 102 records →
    102Dated records
    4Evidence types
    102Cited public sources
    15Source years

    Change ledger

    Recently changed for Linaclotide

    Open all 104 events →

    PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

    Record added

    Linaclotide DailyMed SPL version 40

    DailyMed lists Structured Product Labeling version 40 for the reviewed Linaclotide label family with a published date of 2026-10-19. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.

    PeptideScanner change date
    November 15, 2026
    Cited source date
    October 19, 2026
    Evidence lane
    Regulatory
    Profile status changed

    Linaclotide profile

    We added a plain-language reader guide with cited answers, re-checked the Linzess label, and added Drugs@FDA approval records for Linzess and generic linaclotide.

    PeptideScanner change date
    November 14, 2026
    Evidence lane
    Profile

    Official-source collections

    Source records for Linaclotide

    Open the full research atlas →
    PubMed49

    25 with attributed title, venue, publication-date, and type metadata.

    1. Linaclotide Use for the Treatment of Constipation and Gastrointestinal Symptoms in People With Cystic Fibrosis.Pediatric pulmonology · 2024 12 02
    2. Linaclotide as a Single Agent Bowel Preparation Regimen Before Colonoscopy.The American surgeon · 2024 11 12
    3. Characterization of disulfide bridges containing cyclic peptide Linaclotide and its degradation products by using LC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2024 10 17
    Explore all selected literature →
    ClinicalTrials.gov15

    218 public history versions across these dated registry records; status labels apply only to each cited observation.

    1. NCT05796388Registry update July 29, 2026 · current at observation
    2. NCT03796884Registry update July 22, 2026 · current at observation
    3. NCT05652205Registry update May 14, 2026 · completed at observation
    Explore all selected trial records →Explore all public record history →
    Drugs@FDA4

    Original-submission application metadata connected by exact reviewed active-ingredient names.

    1. ANDA211255Full FDA chronology · original submission status AP 2026-09-24
    2. ANDA209611Full FDA chronology · original submission status AP 2023-02-07
    3. ANDA209564Full FDA chronology · original submission status AP 2021-02-09
    4. NDA202811Full FDA chronology · original submission status AP 2012-08-30
    Explore all selected FDA applications →Explore 25 dated submissions and 34 documents for Linaclotide →
    FDA enforcement reports1

    Recall-enforcement metadata connected only through exact application numbers already mapped to this reviewed profile.

    1. D-0417-2021Class II · report date 2021-06-02
    Explore all exact FDA enforcement reports →
    DailyMed SPL history29

    Version metadata and exact historical ZIP receipts for the reviewed label family, without reproducing or interpreting label text.

    1. SPL version 40Published 2026-10-19 · ZIP SHA-256 39f73b41ea9e…
    2. SPL version 39Published 2026-06-01 · ZIP SHA-256 77c54fc2bf05…
    3. SPL version 38Published 2026-01-16 · ZIP SHA-256 d34462beabf1…
    4. SPL version 36Published 2025-11-17 · ZIP SHA-256 65eb80d6a219…
    5. SPL version 34Published 2024-07-11 · ZIP SHA-256 c7453e08068f…
    Explore all DailyMed label versions →

    Evidence types

    Coverage by source year

    Selected records span August 30, 2012 to October 19, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

    Continue exploring

    Profiles with overlapping source-year coverage

    Open the research atlas →

    These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

    Organizations and trial records named in cited sources

    Organizations named in cited records

    • U.S. National Library of Medicine1
    • U.S. Food and Drug Administration2
    Dated updates connected to this profile · 102

    Updates connected to this profile

    Open the full cross-source timeline →
    1. Regulatory

      Linaclotide DailyMed SPL version 40↗

      DailyMed lists Structured Product Labeling version 40 for the reviewed Linaclotide label family with a published date of 2026-10-19. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.↗

    2. Regulatory

      Drugs@FDA application ANDA211255↗

      The official Drugs@FDA dataset lists original submission 1 for ANDA 211255 with status AP dated 2026-09-24, and names linaclotide among the application record's active ingredients.↗

    3. Literature metadata

      PubMed record PMID 41692643↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 41692643 at 2026-08-10T10:49:08.765Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-02-15. PeptideScanner associated this retained record with the identity slug linaclotide. These dates describe PubMed metadata history, not the article's original publication date.↗

    4. Literature metadata

      PubMed record PMID 42425925↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 42425925 at 2026-08-10T10:49:10.758Z. PubMed recorded a metadata revision date of 2026-08-03 and an Entrez history date of 2026-07-09. PeptideScanner associated this retained record with the identity slug linaclotide. These dates describe PubMed metadata history, not the article's original publication date.↗

    5. Clinical trials

      ClinicalTrials.gov record NCT05796388↗

      PeptideScanner retained ClinicalTrials.gov record NCT05796388 at 2026-08-10T18:10:03.859Z. Its registry update date was 2026-07-29, and PeptideScanner's reviewed identity mapping was linaclotide.↗

    6. Literature metadata

      PubMed record PMID 42523615↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 42523615 at 2026-08-10T18:13:56.783Z. PubMed recorded a metadata revision date of 2026-07-29 and an Entrez history date of 2026-07-29. PeptideScanner associated this retained record with the identity slug linaclotide. These dates describe PubMed metadata history, not the article's original publication date.↗

    7. Literature metadata

      PubMed record PMID 41913506↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 41913506 at 2026-08-10T18:13:46.784Z. PubMed recorded a metadata revision date of 2026-07-28 and an Entrez history date of 2026-03-31. PeptideScanner associated this retained record with the identity slug linaclotide. These dates describe PubMed metadata history, not the article's original publication date.↗

    8. Literature metadata

      PubMed record PMID 42009975↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 42009975 at 2026-08-10T18:13:48.763Z. PubMed recorded a metadata revision date of 2026-07-26 and an Entrez history date of 2026-04-20. PeptideScanner associated this retained record with the identity slug linaclotide. These dates describe PubMed metadata history, not the article's original publication date.↗

    9. Literature metadata

      PubMed record PMID 38962910↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 38962910 at 2026-08-10T18:13:32.376Z. PubMed recorded a metadata revision date of 2026-07-23 and an Entrez history date of 2024-07-04. PeptideScanner associated this retained record with the identity slug linaclotide. These dates describe PubMed metadata history, not the article's original publication date.↗

    10. Clinical trials

      ClinicalTrials.gov record NCT03796884↗

      PeptideScanner retained ClinicalTrials.gov record NCT03796884 at 2026-08-10T18:10:04.224Z. Its registry update date was 2026-07-22, and PeptideScanner's reviewed identity mapping was linaclotide.↗

    11. Literature metadata

      PubMed record PMID 42482900↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 42482900 at 2026-08-10T18:13:56.703Z. PubMed recorded a metadata revision date of 2026-07-22 and an Entrez history date of 2026-07-22. PeptideScanner associated this retained record with the identity slug linaclotide. These dates describe PubMed metadata history, not the article's original publication date.↗

    12. Literature metadata

      PubMed record PMID 42465095↗

      PeptideScanner retained PubMed bibliographic metadata for PMID 42465095 at 2026-08-10T18:13:55.292Z. PubMed recorded a metadata revision date of 2026-07-17 and an Entrez history date of 2026-07-17. PeptideScanner associated this retained record with the identity slug linaclotide. These dates describe PubMed metadata history, not the article's original publication date.↗

    Citations

    Sources

    Coverage and sources →

    Numbered markers in the text point here. Each link opens the original public record.

    1. 1
      LINZESS (linaclotide) capsule · SPL version 39 · published 2026-06-01 ↗

      DailyMed · U.S. National Library of Medicine · Official source · Source checked July 22, 2026

    2. 2
      Drugs@FDA application NDA202811 · original submission status AP · 2012-08-30 · dataset 2026-08-13 ↗

      Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

    3. 3
      Drugs@FDA application ANDA209564 · original submission status AP · 2021-02-09 · dataset 2026-08-13 ↗

      Drugs@FDA via openFDA · Official source · Source checked August 14, 2026

    4. 4
      Drugs@FDA application ANDA209611 · original submission status AP · 2023-02-07 · dataset 2026-08-13 ↗

      Drugs@FDA via openFDA · Official source · Source checked August 14, 2026